Evidence map›Paper›PMID 38483586›Full record

ArticleWorld journal of urology2024

Prognostic factors among patients with pathological Grade Group 5 prostate cancer based on robot-associated radical prostatectomy specimens from a large Japanese cohort (MSUG94).

Takeshi Sasaki, Shin Ebara, Tomoyuki Tatenuma, Yoshinori Ikehata, Akinori Nakayama, Makoto Kawase, Masahiro Toide, Tatsuaki Yoneda, Kazushige Sakaguchi, Jun Teishima and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 1 country.

Takeshi SasakiDepartment of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Shin EbaraDepartment of Urology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
Tomoyuki TatenumaDepartment of Urology, Yokohama City University, Kanagawa, Japan.
Yoshinori IkehataDepartment of Urology, University of Toyama, Toyama, Japan.
Akinori NakayamaDepartment of Urology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
Makoto KawaseDepartment of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.
Masahiro ToideDepartment of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Tatsuaki YonedaDepartment of Urology, Seirei Hamamatsu General Hospital, Shizuoka, Japan.
Kazushige SakaguchiDepartment of Urology, Toranomon Hospital, Tokyo, Japan.
Jun TeishimaDepartment of Urology, Kobe University Graduate School of Medicine, Hyogo, Japan.
Kazuhide MakiyamaDepartment of Urology, Yokohama City University, Kanagawa, Japan.
Hiroshi KitamuraDepartment of Urology, University of Toyama, Toyama, Japan.
Kazutaka SaitoDepartment of Urology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
Takuya KoieDepartment of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.
Fumitaka KogaDepartment of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Shinji UrakamiDepartment of Urology, Toranomon Hospital, Tokyo, Japan.
Takahiro InoueDepartment of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan. tinoue28@med.mie-u.ac.jp.
Gifu University · JPMie University · JPTokyo Metropolitan Komagome Hospital · JPToranomon Hospital · JPUniversity of Toyama · JPYokohama City University · JPDokkyo Medical University · JPHiroshima City Asa Citizens Hospital · JPKobe University · JPSeirei Hamamatsu General Hospital · JPSocial Insurance Saitama Chuo Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThere are no definitive prognostic factors for patients with pathological Grade Group 5 (pGG 5) prostate cancer (PCa) undergoing robot-associated radical prostatectomy (RARP). This study aimed to explore the prognostic factors among patients with pGG 5 PCa in a large Japanese cohort (MSUG94).

methodsThis retrospective, multi-institutional cohort study was conducted between 2012 and 2021 at ten centers in Japan and included 3195 patients. Patients with clinically metastatic PCa (cN1 or cM1) and those receiving neoadjuvant and/or adjuvant therapy were excluded. Finally, 217 patients with pGG5 PCa were analyzed.

resultsThe median follow-up period was 28.0 months. The 3- and 5-year biochemical recurrence-free survival (BCRFS) rates of the overall population were 66.1% and 57.7%, respectively. The optimal threshold value (47.2%) for the percentage of positive cancer cores (PPCC) with any GG by systematic biopsy was chosen based on receiver operating characteristic curve analysis. Univariate analysis revealed that the prostate-specific antigen level at diagnosis, pT, pN, positive surgical margins (PSMs), lymphovascular invasion, and PPCC were independent prognostic factors for BCRFS. A multivariate analysis revealed that PSMs and PPCC were independent prognostic factors for BCRFS. Using these two predictors, we stratified BCRFS, metastasis-free survival (MFS), and castration-resistant PCa-free survival (CRPC-FS) among patients with pGG 5 PCa.

conclusionThe combination of PSMs and PPCC may be an important predictor of BCRFS, MFS, and CRPC-FS in patients with pGG 5 PCa undergoing RARP.

Indexed as

Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantRoboticsRobotic Surgical ProceduresCohort StudiesDisease-Free SurvivalHumansJapanMalePrognosisProstatectomyProstate-Specific AntigenRetrospective StudiesProstate-Specific AntigenPathological Grade Group 5Percentage of positive cancer coresPositive surgical marginsProstate cancer

Identifiers

PMID38483586
OpenAlexW4392818241

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.